Ro 60-0175 fumarate
Potent, selective 5-HT2 receptor agonist; shows selectivity for the 5-HT2C subtype (pKi values are 9, 7.5, 5.4, 5.2 and 5.6 for human 5-HT2C, 2A, 1A, 6 and 7 receptors respectively). Centrally active following oral or systemic administration in vivo.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 342.75. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.92 mL||14.59 mL||29.18 mL|
|5 mM||0.58 mL||2.92 mL||5.84 mL|
|10 mM||0.29 mL||1.46 mL||2.92 mL|
|50 mM||0.06 mL||0.29 mL||0.58 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Damjanoska et al (2003) Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol-l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine2C receptor agonist. J.Pharmacol.Exp.Ther. 304 1209 PMID: 12604698
Kennett et al (2000) Effects of Ro 60 0175, a 5-HT2C receptor agonist, in three animal models of anxiety. Eur.J.Pharmacol. 387 197 PMID: 10650160
Martin et al (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J.Pharmacol.Exp.Ther. 286 913 PMID: 9694950
Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive J.Med.Chem. 56 1211 PMID: 23301527
If you know of a relevant reference for Ro 60-0175 fumarate, please let us know.
View Related Products by Product Action
Keywords: Potent selective 5-HT2C agonists Serotonin Receptors Ro60-0175 5-HT2C Receptors
7 Citations for Ro 60-0175 fumarate
Citations are publications that use Tocris products. Selected citations for Ro 60-0175 fumarate include:
Martin et al (2015) 5-HT2C receptor desensitization moderates anxiety in 5-HTT deficient mice: from behavioral to cellular evidence. Synapse 18 PMID: 25522398
Kasper et al (2015) Serotonin-2C receptor agonists decrease potassium-stimulated GABA release in the nucleus accumbens. J Neurophysiol 69 78 PMID: 25382408
Martin et al (2014) Effect of genetic and pharmacological blockade of GABA receptors on the 5-HT2C receptor function during stress. J Neurochem 131 566 PMID: 25113583
Craige and Unterwald (2013) Serotonin (2C) receptor regulation of cocaine-induced conditioned place preference and locomotor sensitization. Behav Brain Res 238 206 PMID: 23103406
Manvich et al (2012) Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 341 424 PMID: 22328576
Yu and Yamaguchi (2010) Endogenous serotonin acts on 5-HT2C-like receptors in key vocal areas of the brain stem to initiate vocalizations in Xenopus laevis. J Biol Chem 103 648 PMID: 19955293
Yu and Yamaguchi (2009) 5-HT2C-like receptors in the brain of Xenopus laevis initiate sex-typical fictive vocalizations. J Neurophysiol 102 752 PMID: 19474172
Do you know of a great paper that uses Ro 60-0175 fumarate from Tocris? If so please let us know.
Literature in this Area
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.